Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inflammation may predict success of targeted cancer therapy

NCT ID NCT07241403

Knowledge-focused Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 698 people with metastatic colorectal cancer to see if chronic inflammation changes how well bevacizumab (a targeted therapy) plus chemotherapy works. Researchers measured inflammation markers in the blood and analyzed immune proteins to find clues about treatment resistance and survival. The goal was to better understand who benefits from this combination therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which patients with metastatic colorectal cancer will benefit most from bevacizumab combined with chemotherapy.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and the findings may not apply to all patients or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

698 people

The number who actually took part.

Started

Jan 2018

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

In this study, all enrolled patients received first-line CT or Bev/CT based on the decisions made by both patients and clinicians. The treatment regimens included: (1) oxaliplatin-based CT (FOLFOX/XELOX, OX), (2) irinotecan-based CT (FOLFIRI/ XELIRI, IRI), (3) Bev combined with oxaliplatin-based CT (Bev/OX), and (4) Bev combined with irinotecan-based CT (Bev/IRI). All the patients underwent at least two cycles of Bev/CT until they either withdrew from the disease, experienced disease progression, or encountered intolerable toxic effects.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of mCRC; * Aged over 18 years; * Must be able to receive the further treatment in the hospital. Exclusion Criteria: * More than two types of malignancies; * Bacterial or virus infection within one month before diagnosis; * Taken anti-inflammatory drugs or other forms of chemotherapy before their diagnosis; * participants whose follow-up was interrupted three months ago without reaching any endpoint.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bevacizimab are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bevacizimab Colorectal cancer Inflamation Resistance

Contacts and locations

Locations

  • The second hospital of Nanchang university

    Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.